In the former, somatic mutation of 53BP1 in BRCA-deficient tumor [62] has been shown to promote resistance against PARP inhibitor, whereas the latter undergoes further genetic alteration to regain BRCA1/2 wild-type function [63]. The gene discussed is PARP1; the disease is neoplasm.